Guido Magni

Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations.

Develops novel anticancer compounds

Provides biopharmaceutical products

Discovers and develops cancer therapeutics and drugs

Provides biopharmaceutical research and development services

Manufactures and markets novel therapies for severe retinal neurodegenerative diseases

Engages in discovery and development of anti-cancer drugs

Develops personalized cancer treatments

Operates as an oncology company that develops immunotherapies

Acts as an alternative investment manager

Operates as a biotechnology company that develops antibodies for the treatment of cancer

Operates as biopharmaceutical company which develops novel anticancer compounds

Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer